ArticleOncotarget2018
Both the intratumoral immune and microbial microenvironment are linked to recurrence in human colon cancer: results from a prospective, multicenter nodal ultrastaging trial.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Impact of Gut Microbiota on the Clinical Course and Treatment Outcomes of Colorectal Cancer-A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Review
- Molecular mechanisms of bacteria-mediated cancer immunotherapy: from intratumoral microbiota to engineered therapeutics.Frontiers in immunology · 2026Review
- Integrative pan-cancer analysis of intratumoral microbial communities for biomarker discovery and diagnostic modeling.Journal of translational medicine · 2025Article
- Mammary tissue microbiome analysis in PyMT mice reveals Methylobacteria as a commensal organism with potential therapeutic applications.Translational oncology · 2025Article
- Intratumoral Microbiota: Insights from Anatomical, Molecular, and Clinical Perspectives.Journal of personalized medicine · 2024Review
- Exploiting bacteria for cancer immunotherapy.Nature reviews. Clinical oncology · 2024Review
- Intratumoral Microbiome: Foe or Friend in Reshaping the Tumor Microenvironment Landscape?Cells · 2024Review
- Hepatitis B virus-related hepatocellular carcinoma exhibits distinct intratumoral microbiota and immune microenvironment signatures.Journal of medical virology · 2024Article
- The intratumor microbiome is associated with microsatellite instability.Journal of the National Cancer Institute · 2023Article
- Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy.Signal transduction and targeted therapy · 2023Review
- Intratumoral microbiota: implications for cancer onset, progression, and therapy.Frontiers in immunology · 2023Review
- Intratumor microbiota in cancer pathogenesis and immunity: from mechanisms of action to therapeutic opportunities.Frontiers in immunology · 2023Review
- Enterotypical Prevotella and three novel bacterial biomarkers in preoperative stool predict the clinical outcome of colorectal cancer.Microbiome · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
Colon cancer (CC) is the third most common cancer diagnosed in the United States and the incidence has been rising among young adults. We and others have shown a relationship between the immune infiltrate and prognosis, with improved disease-free survival (DFS) being associated with a higher expression of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.